CryoPort (CYRX)

The company offers an integrated set of capabilities that includes cryogenic logistics, temperature-controlled transport, biostorage, bioservices, cryopreservation support, and the manufacture of cryogenic systems. Its solutions are used by biopharmaceutical companies, contract manufacturers, clinical trial sponsors, and other life sciences organizations that require reliable handling of high-value, sensitive biological products. Because temperature excursions can compromise product quality or patient treatment schedules, the company’s services are designed around monitoring, chain-of-condition information, specialized packaging, and operational controls.

CryoPort reports its business through two main segments: Life Sciences Services and Life Sciences Products. The services segment contributes the larger share of revenue and reflects the company’s position as a logistics and supply chain partner for advanced therapies. The products segment supports customers with equipment and systems used in cryogenic storage and handling.

The company is closely tied to the growth of the cell therapy, gene therapy, reproductive medicine, and broader biostorage markets. Its value proposition is based on specialized infrastructure, regulatory-aware processes, and the ability to support materials that require ultra-low temperature or cryogenic conditions across global networks.